The Biotechnology Industry In NJ Adds More Companies And Staff – (EXEL, ZLCS, SPPI)

Google and facebook trends

Biotech companies with operations in New Jersey continues to reveal vitality, experiencing major growth in both the number of companies operating in the State and the number of staff members for those companies, according to the results of a survey conducted by Ernst & Young.

The biotechnology industry in New Jersey had added more than 40 companies from over 300 in a previous BioNJ study in July 2010 to more than 340 today, representing a raise of about 13 percent, according to the study, Biotech in New Jersey: Finding Its Way Through Continuing Challenges.

Exelixis, Inc. (NASDAQ:EXEL)

Exelixis, Inc. (NASDAQ:EXEL) recently declared that it aims to tender, subject to market and other circumstances, 20,000,000 shares of its common stock and $225 million aggregate principal amount of exchangeable senior subordinated notes due in 2019 in concurrent underwritten public offerings.

In the last trading session, Exelixis, Inc. (NASDAQ:EXEL) slipped -6.46% and closed at $4.28 with the total traded volume of 9.94 million shares more than the average volume of 2.02 million. Stock price 52 weeks high was $8.25 and 52 weeks low price was $3.94.

Zalicus Inc (NASDAQ:ZLCS)

Zalicus Inc (NASDAQ:ZLCS) rose 8.00% and closed at $1.35 with the total traded volume of 7.66 million shares in last trading session. ESV is trading above the 50 day moving average and higher than the 200 day moving average.

Zalicus Inc. (Zalicus) is a biopharmaceutical company that discovers and develops treatments for patients suffering from pain and immuno-inflammatory diseases.

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) declined -14.25% with the closing price of $11.81. The overall volume in the last trading session was 7.31 million shares. Its fifty two week range was $6.94-$13.44. The total market capitalization remained $702.84 million.

SPPI is ahead of its 52 week low with 70.17% and its last month price volatility remained 5.34%. Its beta coefficient was 1.44 with a target price of $23.33. Company’s current year earnings per share grew 184.84%.


Leave a Reply

Your email address will not be published. Required fields are marked *